Research
An unprecedented 10 Innovator Awards go out to scientists for their exciting research. Despite…
Announcing our 2021 Innovator Award recipients! These brilliant scientists are exploring new ideas about why hydrocephalus develops and testing new treatments to improve long term outcomes.
This blog explains the difference between white and grey matter injuries and their effects on the brain.
Rhaeos, Inc. was awarded an NIH grant to advance their development of wearable sensors to detect failed shunts in patients with hydrocephalus.
The concept of Generalizability in research studies is especially important for individuals living with hydrocephalus because there are so many different causes.
Earlier this year, Anuncia Inc., a medical device company focused on the development of treatment devices for hydrocephalus and other cerebrospinal fluid (CSF) disorders, announced that the ReFlowTM System Mini received the U.S Food and Drug Administration (FDA) Breakthrough Device Designation. The ReFlowTM System Mini is the next generation version of the commercial ReFlowTM Ventricular System.
A recent study explored how neonatal intensive care units (NICUs) can better prepare families that receive a diagnosis of posthemorrhagic hydrocephalus of prematurity (PHHP).
In this installment of our Meet the Innovator Award Grantees Blog Series, we interviewed Dr. Aditya S. Pandey, one of four scientists who received a 2020 Innovator Award. Dr. Pandey’s team is testing the use of acetazolamide (Diamox) directly into the ventricles to determine if it can prevent hydrocephalus.
French startup Neurallys is developing an implantable intracranial pressure (ICP) monitor for hydrocephalus. The device continuously measures, records and sends ICP data to a patient’s smartphone via a Bluetooth connection.
Learn about Dr. Stavros Taraviras, one of four scientists who received a Hydrocephalus Association 2020 Innovator Award. Dr. Taraviras is working to turn scar tissue back into ependymal cells as a novel therapeutic strategy for hydrocephalus.
In the United States, the standard treatment for idiopathic Normal Pressure Hydrocephalus (iNPH) patients is a ventriculoperitoneal shunt (VPS). But a new study explores the effectiveness of lumboperitoneal shunts (LPS), which have also been shown to improve iNPH symptoms and are widely used in Japan.
A new study published in the Journal of Neurosurgery: Pediatrics assessed quality of life and mental wellbeing of both children with hydrocephalus and their caregivers.
For our Meet the Innovator Award Grantees Blog Series, we interviewed Dr. Engin Deniz, one of four scientists who received a 2019 Innovator Award. Through his research, he hopes to determine how cilia, small hair like structures that move CSF, contribute to post-traumatic hydrocephalus.
A new study found that shunting improved quality of life for people living with Idiopathic Normal Pressure Hydrocephalus (iNPH).
In the second installment of our Meet the Innovator Awardees Blog Series, we interviewed Dr. Brandon A. Miller, one of four scientists who received an Innovator Award grant.
In our first installment of our Meet the Innovator Awardees Blog Series, we interview Dr. Bernadette Holdener, one of four scientists who received a Hydrocephalus Association 2019 Innovator Award.
There is a lot we do not know about how hydrocephalus develops and how to best treat the condition across our many communities. Our 2019 Innovator Award recipients are looking to change that.
Families and researchers from across the country came together on Nov. 3 to celebrate the 10th Anniversary of HA’s Research Initiative. The event, held in St. Louis, MO, highlighted the successes of our research investments and honored the trailblazers who started it all.
The Hydrocephalus Clinical Research Network (HCRN) conducted a study to determine which babies under two years old with hydrocephalus have the best chance of success with an ETV-CPC procedure. In her blog, Dr. Jenna Koschnitzky, National Director of Research Programs, explains why the findings of this study are important when determining if a baby under two years old should receive a shunt or undergo the ETV-CPC procedure.
Patients diagnosed with idiopathic Normal Pressure Hydrocephalus (iNPH) are typically treated by having a shunt placed surgically. A new clinical trial will determine whether or not shunts are an effective form of treatment for iNPH patients.